With this research we intend to fill the gap described in the previous chapter by:1) Detecting functional network changes in several causes of early-onset dementia and to characterize the specific changes for each dementia cause.2) Relating specific…
ID
Source
Brief title
Condition
- Structural brain disorders
- Dementia and amnestic conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary end points are differences in measures of coupling and organization of
MEG functional brain networks between the subject groups. These measures
(specified below) are computed after signal pre-processing described by
Hillebrand et al. in 2012 with the title: "Frequency-dependent functional
connectivity within resting-state networks: an atlas-based MEG beamformer
solution".
Functional coupling measure as main study parameter is the Phase Lag Index
(PLI). Network measures that will be computed are: clustering coefficient, path
length, degree correlation, and modularity (with Synchronization Likelihood as
coupling measure (18;19). Correlations of these measures with cognitive
performance are generated in the patient groups.
Secondary outcome
Secundary endpoints of the study are:
- relationship of basic quantitative measures (band power, peak frequency) with
cognition.
- location of important points in the network (hubs) and the relationship with
cognitive performance.
- The Minimal Spanning Tree (MST) configuration, as a different way to
construct a brain network (20), and the relationship with cognitive performance
in the patients.
Background summary
Dementia has a devastating effect on quality of life for both late- and early
onet patients. Early-onset dementia, defined as the start of symtpoms before
the age of 70, can have several causes, the most prevalent cause is Alzheimer*s
disease (AD). In elderly patients, AD consist of progressive memory impairment
followed by global cognitive decline. Early-onset AD patients more often show
focal impairments like aphasia and apraxia and a more rapid cognitive decline.
These symptoms are often referred to as *non-memory* or *atypical* AD
presentation.
Other forms of dementia, such as frontotemporal dementia (FTD), semantic
dementia (SD), primary progressive aphasia (PPA), corticobasal dementia (CBD),
progressive supranuclear palsy (PSP) or dementia with Lewy Bodies (DLB),
although rare, are more common in younger patients and may mimic early-onset AD
clinically. Most often no structural abnormalities are seen on magnetic
resonance imaging (MRI) scanning of the brain, posing diagnostic difficulties.
Brain activity can be measured by magnetoencephalography (MEG). Of this
activity, functional networks can be derived by establishing the coupling
between brain regions.
Study objective
With this research we intend to fill the gap described in the previous chapter
by:
1) Detecting functional network changes in several causes of early-onset
dementia and to characterize the specific changes for each dementia cause.
2) Relating specific network changes to specific cognitive deficits.
This will provide insight on the development of functional changes due to the
dementias and if distinct patterns are found, this knowledge aids in the
diagnostic process.
Study design
After completing a written informed consent, all patients fulfilling the
inclusion criteria, as will be described in the next chapter, will undergo an
MEG measurement at the MEG centre of the VU medical centre in Amsterdam. This
study is designed as an observational cross-sectional study. For control
participants which don't have an MRI/NPO formt he past three years, these will
be conducted as well.
Study burden and risks
There is no direct therapeutic effect or other benefit in this study; clinical
decision making will not be based on the results. The test is non-invasive,
short of duration and pain free. Risks associated with participation are
negligible, and the burden is minimal. Unexpected findings which could lead to
medical treatment will be discussed with participants.
De Boelelaan 1117
Amsterdam 1071 HV
NL
De Boelelaan 1117
Amsterdam 1071 HV
NL
Listed location countries
Age
Inclusion criteria
- For the patient group: diagnosis of one of the following types of dementia: AD, FTD, SD/PPA, CBD or PSP/DLB.
- For the control group: no past history of cognitive disabilities or other neurological or other disease possibly interfering with the analysis.
- MMSE-score of 18 or higher.
- Age 70 years or younger at the time of participation.
- Written informed consent.
Exclusion criteria
- Previous brain surgery.
- Insufficient mastery of Dutch or English language.
- Conditions that will cause excessive MEG artefact (cardiac pacemaker / cardiac or neural defibrillators, metal fragments in the eyes, metal plates, pins or bolts in head, any magnetic implantation / implantations made from iron (ferrous products)
- For the patient group: lack of MRI examination performed in the last three years or lack of neuropsychological examination performed in the last twelve months.
- For the control group: no conducted MRI in the past three years and unable to undergo MRI examination or neuropsychological testing, cognitive deficits.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL41647.029.13 |